Orphan Genetic Disease – making testing a reality

Making pharmacogenetic testing a reality in a community pharmacy.

OBJECTIVE To provide information for community pharmacies considering implementation of a pharmacogenetic testing service. SETTING A single community pharmacy from a regional chain. PRACTICE DESCRIPTION Community pharmacists at the study site routinely provide pharmacy services including medication therapy management, immunizations, point-of-care testing, blood pressure monitoring, and diab...

Making Mobile Augmented Reality A Reality

Recent advances in mobile device technology have freed augmented reality (AR) applications from the constraints of desktops, laptops and head-mounted displays. But they are met with a lack of guidelines on the design and user interactions of mobile device-based AR systems. The situation for developers is further exacerbated by closed-license environments and inflexible solutions. We provide an ...

Huntington Disease: The Complexities of Making and Disclosing a Clinical Diagnosis After Premanifest Genetic Testing

The management of patients and families affected by Huntington disease (HD) is complicated by several factors, both practical and ethical. It can be difficult to determine the onset of clinically manifest HD (mHD). In addition, it can be challenging to decide when to disclose the diagnosis to the affected individual. Firstly, the features of HD, an incurable, inherited, neurocognitive disorder ...

Unraveling myths of platelet function and genetic testing the road to making tailored antiplatelet therapy a reality.

Clopidogrel therapy is associated with a broad variability in pharmacodynamic (PD) response, and individuals with high on-treatment platelet reactivity (HPR) have an increased risk of recurrent ischemic events, including stent thrombosis (1,2). Given the pivotal role of this platelet-inhibiting strategy in patients with acute coronary syndrome and undergoing percutaneous coronary interventions ...

Making maritime TBMD a reality